187 results on '"Diez-Campelo M"'
Search Results
52. P2442Assessment of iron overload and cardiac disease in patients with transfusion-dependent myelodysplastic syndromes with cardiac magnetic resonance new sequences
53. Clinical and Biological Significance of Y Chromosome Loss in a Series of 2,423 Male Patients with MDS and CMML
54. Calculating IPSS-R by Enumerating Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Prediction in MDS with Erythroid Predominance
55. The Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts can be Improved by Considering Bone Marrow Blasts from Nonerythroid Cells
56. A TWO-STEP APPROACH FOR THE ANALYSIS OF SPLICING GENES IN MYELODYSPLASTIC SYNDROMES WITH RING SIDEROBLASTS
57. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
58. Ex vivo identification and characterization of a population of CD13(high) CD105(+) CD45(-) mesenchymal stem cells in human bone marrow
59. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival
60. 244 MYELOFIBROSIS (MF) AS A PROGNOSTIC TOOL FOR OVERALL SURVIVAL IN MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE EVALUATION INCLUDING MUTATIONAL ANALYSIS BY NEXT GENERATION SEQUENCING (NGS)
61. 118 A PHASE 2 STUDY OF AZACITIDINE AND EPOETIN-BETA IN UNTREATED RBC-TRANSFUSION DEPENDENT LOWER-RISK MDS PATIENTS
62. Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy
63. 261 - What is the Outcome of Patients in the Intermediate IPSS-R Score Group? Spanish Approach for Better Stratification with Classical Tools
64. 238 - Calculating IPSS-R by Enumerating Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Prediction in MDS with Erythroid Predominance
65. 235 - The Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts can be Improved by Considering Bone Marrow Blasts from Nonerythroid Cells
66. 208 - Clinical and Biological Significance of Y Chromosome Loss in a Series of 2,423 Male Patients with MDS and CMML
67. 196 - Mutational Status of Mesenchymal Stem Cell in Myelodysplastic Syndromes Patients
68. 163 - DNA Repair Genes Transcriptome in Chronic Myelomonocytic Leukemia
69. 87 - Mutational and Clonal Dynamics During Progression from MDS to SAML by Whole-Exome and Targeted-Deep Sequencing
70. 81 - Sintra-Rev Clinical Trial: Preliminary Analysis of Efficacy and Safety at Week 12 of Treatment in MDS Del(5Q) and Transfusion Independence
71. 10 - Mutational Signature and Clonal Architecture of Low Risk Myelodysplastic Syndromes with Del(5Q)
72. P-234 Mesenchymal stromal cells from MDS with 5q- show different genetic and epigenetic changes compared to those from other low-risk MDS
73. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients
74. 64 A retrospective time-dependent comparative analysis of the impact of lenalidomide on outcomes in lower risk MDS with chromosome 5q deletion
75. 315 Prognostic impact of performance status and comorbidity on the overall survival of patients with myelodysplastic syndromes: A prospective evaluation
76. 235 An integrative analysis of methylation and gene expression profiling in low-risk myelodysplastic syndromes (MDS)
77. 78 A small subset of mesenchymal stem cells from MDS patients harbour the cytogenetic abnormality of haematopoietic cells
78. 261 ERYTHROLEUKEMIA APPEARS TO BE A CONTINUUM OF MDS WITH ERYTHROID HYPERPLASIA AND SHARES OUTCOME AND CYTOGENETIC FEATURES WITH RAEB-1 WITH ≥50% ERYTHROPOIESIS
79. 171 A TWO-STEP APPROACH FOR THE ANALYSIS OF SPLICING GENES IN MYELODYSPLASTIC SYNDROMES WITH RING SIDEROBLASTS
80. 29 MICROVESICLES/EXOSOMES DERIVED FROM BONE MARROW MESENCHYMAL STROMAL CELLS (MSC) ARE INVOLVED IN THE INTERCELLULAR COMMUNICATION BETWEEN HEMATOPOIETIC CELLS AND BM MICROENVIRONMENT IN MDS PATIENTS
81. The role of immature platelet fraction in acute coronary syndrome
82. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population
83. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes
84. Reduced Intensity Conditioning Unrelated Transplant Plus Cyclosporine and MMF as GVHD Prophylaxis: Results of a Prospective Study.
85. P-054 Application of array-based karyotyping as a complementary tool in the diagnosis of myelodysplastic syndromes and related myeloid neoplasms
86. 258 Down-regulation of DICER1, DROSHA and microRNAs in MSC from MDS compared to healthy controls
87. 108 SNP-A karyotyping in primary myelodysplastic syndromes with unsuccessful routine cytogenetic testing
88. 65 Simultaneous analysis of the expression of 14 genes with individual prognostic value in patients with MDS at diagnosis
89. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft versus host disease (GVHD)
90. Pentostatin in refractory acute and chronic GVHD. A single center experience
91. STUDY OF PRE-EXISTING MUTATIONS IN HEMATOPOYETIC CELLS OF THE BONE MEDULA IN PATIENTS WITH MYELOID NEOPLASIAS RELATED TO THERAPY
92. COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
93. Allogeneic stem cell transplant for myelodysplastic syndromes: results of 291 patients from Spanish MDS Registry. Subanalysis on low-risk patients
94. THE STUDY OF CELL CHIMERISM AFTER ALLOGENEIC TRANSPLANTATION CAN IMPROVE THE MANAGEMENT OF PATIENTS WITH HEMATOPOIETIC MYELOID MALIGNANCIES
95. SPRESAS (SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY) SUBANALYSIS: IMPACT OF COMORBIDITIES AND CENTER LEVEL ON RESPONSE TO ESAS IN LOWER RISK MDS
96. GERM PREDISPOSITION IN MYELODYSPLASTIC SYNDROMES IN YOUNG ADULTS WITHOUT PREVIOUS ORGANIC DYSFUNCTION: NEW FINDING OF DELETERIOUS VARIANTS IN GENES RESPONSIBLE FOR MICROSATELLITE INSTABILITY
97. SPRESAS (SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY): THE LARGEST RETROSPECTIVE STUDY OF TREATMENT WITH ESAS IN LOWER RISK MDS
98. ANALYSIS OF CONCURRENT SOMATIC MUTATIONS WITH SF3B1 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ITS CLINICAL, BIOLOGICAL AND PROGNOSTIC IMPLICATION
99. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes
100. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.